Real-world studies have documented reduced craving reduction, decreased desire to drink and an overall reduction in alcohol consumption in people with obesity and alcohol use disorder on tirzepatide or semaglutide.28 Our analysis also noted a nearly 4.45% increase in circulating serum calcitonin levels. The gene discussed is CALCA; the disease is obesity due to melanocortin 4 receptor deficiency.